Dr. Karmali on the Future of CAR T-Cell Therapy in DLBCL
Reem Karmali, MD
Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
As cellular immunotherapy takes the forefront, CAR T-cell therapy is an encouraging modality of therapy, says Karmali. However, there are going to be challenges, such as toxicity management and how to incorporate CAR T-cell therapy into existing modalities of therapy.
Thus far, Karmali is optimistic about the CAR T-cell therapy results and believes it will drastically impact DLBCL.